{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:35:53Z","timestamp":1793763353010,"version":"4.6.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PRIN2022"],"award-info":[{"award-number":["PRIN2022"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["CUP 20225XTNZE"],"award-info":[{"award-number":["CUP 20225XTNZE"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejps.2026.107519","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:44:00Z","timestamp":1774770240000},"page":"107519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Sustainable chemistry and preclinical characterization of RC-106\u00b7HCl: A brain-penetrant pan sigma receptor modulator for glioblastoma"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-035X","authenticated-orcid":false,"given":"Noemi","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Listro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cavassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Palazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cambiaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Rosario","family":"Buffelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio Massimo","family":"Dondio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Rossino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Linciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Collina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-5952","authenticated-orcid":false,"given":"Anna","family":"Tesei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107519_bib0001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2021.02.019","article-title":"High-pressure oxygen rewires glucose metabolism of patient-derived glioblastoma cells and fuels inflammasome response","volume":"506","author":"Arienti","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2026.107519_bib0002","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/acs.jnatprod.5b00947","article-title":"Feeling Nature\u2019s PAINS: natural products, natural product drugs, and pan assay interference compounds (PAINS)","volume":"79","author":"Baell","year":"2016","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejps.2026.107519_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40508-016-0051-z","article-title":"Tools and techniques for solvent selection: green solvent selection guides","volume":"4","author":"Byrne","year":"2016","journal-title":"Sustain. Chem. Process."},{"key":"10.1016\/j.ejps.2026.107519_bib0004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/13543776.2017.1276569","article-title":"Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016)","volume":"27","author":"Collina","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejps.2026.107519_bib0017","series-title":"Introduction to infrared and Raman spectroscopy","author":"\\Colthup","year":"1975"},{"key":"10.1016\/j.ejps.2026.107519_bib0005","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3390\/ijms21239012","article-title":"Pan-Sigma receptor modulator RC-106 induces terminal unfolded protein response In In vitro pancreatic cancer model","volume":"21","author":"Cortesi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2026.107519_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-19557-8","article-title":"Redefine tumor spheroids heterogeneity via PCA-coupled biophysical characterization","volume":"15","author":"Cristaldi","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2026.107519_bib0007","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1021\/jm5019093","article-title":"PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS","volume":"58","author":"Dahlin","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107519_bib0008","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.3390\/cancers13153750","article-title":"Glioblastoma: emerging treatments and novel trial designs","volume":"13","author":"Di Nunno","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2026.107519_bib0009","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.0c02265","article-title":"Recent advances in the development of Sigma receptor ligands as cytotoxic agents: a medicinal chemistry perspective","volume":"64","author":"Fallica","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107519_bib0010","doi-asserted-by":"crossref","first-page":"vii95","DOI":"10.1093\/neuonc\/noac209.354","article-title":"DDEL-08. NOVEL combination therapy using Pi3kinase inhibition and immune based therapy for the treatment of Glioblastoma Multiforme","volume":"24","author":"Fonkem","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0011","doi-asserted-by":"crossref","unstructured":"Fr\u00f8yen, P., Juvvik, P., 1995. One-pot synthesis of secondary or tertiary amines from alcohols and amines via alkoxyphosphonium salts. https:\/\/doi.org\/10.1016\/0040-4039(95)02046-2.","DOI":"10.1002\/chin.199615090"},{"key":"10.1016\/j.ejps.2026.107519_bib0012","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejps.2026.107519_bib0013","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cryst14060484","article-title":"Crystal morphology prediction models and regulating methods","volume":"14","author":"Gao","year":"2024","journal-title":"Crystals"},{"key":"10.1016\/j.ejps.2026.107519_bib0014","doi-asserted-by":"crossref","first-page":"E1408","DOI":"10.3390\/molecules22091408","article-title":"Sigma receptor (\u03c3R) ligands with antiproliferative and anticancer activity","volume":"22","author":"Georgiadis","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2026.107519_bib0015","doi-asserted-by":"crossref","first-page":"S422","DOI":"10.1016\/j.annonc.2024.08.555","article-title":"486P Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma","volume":"35","author":"Gr\u00f6nros","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0016","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1016\/S1470-2045(24)00190-6","article-title":"A brave new framework for glioma drug development","volume":"25","author":"Hotchkiss","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0018","series-title":"Press release: Invios Reports Promising Phase 1b Results For Cell Therapy APN401 in Advanced Solid Tumors","year":"2025"},{"key":"10.1016\/j.ejps.2026.107519_bib0019","series-title":"Global Oncology Trends 2025: Adopting new Therapies As Modalities Shift and Expenditures Rise. IQVIA","author":"IQVIA","year":"2025"},{"key":"10.1016\/j.ejps.2026.107519_bib0020","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1016\/j.bmcl.2009.08.045","article-title":"Using the Golden Triangle to optimize clearance and oral absorption","volume":"19","author":"Johnson","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2026.107519_bib0021","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1021\/acs.chemrev.1c00631","article-title":"Green chemistry in the synthesis of pharmaceuticals","volume":"122","author":"Kar","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejps.2026.107519_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13616","article-title":"Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment","volume":"7","author":"Katsushima","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2026.107519_bib0023","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11060-023-04287-6","article-title":"Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors","volume":"163","author":"Lazzarini","year":"2023","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107519_bib0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3389\/fchem.2020.00495","article-title":"Exploring the RC-106 chemical space: design and synthesis of novel (E)-1-(3-arylbut-2-en-1-yl)-4-(substituted) piperazine derivatives as potential anticancer agents","volume":"8","author":"Listro","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejps.2026.107519_bib0026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12885-019-5700-7","article-title":"Sigma-2 receptor\/TMEM97 agonist PB221 as an alternative drug for brain tumor","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejps.2026.107519_bib0027","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0028","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0959-8049(22)00847-4","article-title":"NMS-173, a potent, covalent second generation IDH1\/IDH2 inhibitor","volume":"174","author":"Magnaghi","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2026.107519_bib0029","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/nox144","article-title":"Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma","volume":"20","author":"Mandel","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0030","series-title":"Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma [WWW Document]","year":"2025"},{"key":"10.1016\/j.ejps.2026.107519_bib0031","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Nabors","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ejps.2026.107519_bib0032","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","article-title":"Breaking barriers for glioblastoma with a path to enhanced drug delivery","volume":"14","author":"Noorani","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2026.107519_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01141","article-title":"Small-molecule modulators of Sigma1 and Sigma2\/TMEM97 in the context of cancer: foundational concepts and emerging themes","volume":"10","author":"Oyer","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107519_bib0034","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41592-021-01291-4","article-title":"MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity","volume":"18","author":"Peirsman","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejps.2026.107519_bib0035","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1021\/acs.jmedchem.5c00279","article-title":"Discovery of a potent, selective, and brain-penetrant checkpoint kinase 1 inhibitor, BEN-28010, for the treatment of glioblastoma","volume":"68","author":"Rawling","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107519_bib0036","doi-asserted-by":"crossref","first-page":"1431382","DOI":"10.3389\/fchem.2024.1431382","article-title":"A green Heck reaction protocol towards trisubstituted alkenes, versatile pharmaceutical intermediates","volume":"12","author":"Rossino","year":"2024","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejps.2026.107519_bib0037","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ejmech.2016.08.067","article-title":"Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents","volume":"124","author":"Rui","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107519_bib0038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/cei.13518","article-title":"Protease inhibitors elicit anti-inflammatory effects in CF mice with Pseudomonas aeruginosa acute lung infection","volume":"203","author":"Sandri","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejps.2026.107519_bib0039","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejps.2026.107519_bib0041","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3390\/biomimetics10120794","article-title":"Biomimetic phantoms in X-ray-based radiotherapy research: a narrative review","volume":"10","author":"Sch\u00fcltke","year":"2025","journal-title":"Biomimetics"},{"key":"10.1016\/j.ejps.2026.107519_bib0042","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1158\/1538-7445.AM2025-3043","article-title":"Abstract 3043: preclinical efficacy assessment of brincidofovir against glioblastoma","volume":"85","author":"Seo","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2026.107519_bib0043","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11060-022-04039-y","article-title":"Analysis of factors leading to early termination in glioblastoma-related clinical trials","volume":"158","author":"Shah","year":"2022","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0044","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2026.107519_bib0045","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fphar.2019.00490","article-title":"Anti-tumor efficacy assessment of the Sigma Receptor Pan modulator RC-106. A promising therapeutic tool for pancreatic cancer","volume":"10","author":"Tesei","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107519_bib0046","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3389\/fphar.2018.00711","article-title":"Sigma receptors as endoplasmic reticulum stress \u201cgatekeepers\u201d and their modulators as emerging new weapons in the fight against cancer","volume":"9","author":"Tesei","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107519_bib0047","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","article-title":"The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?","volume":"20","author":"Vanderbeek","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0048","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/acsptsci.4c00711","article-title":"Recent advances in the development of Sigma receptor (Radio)ligands and their application in tumors","volume":"8","author":"Wang","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejps.2026.107519_bib0049","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejps.2026.107519_bib0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1054\/bjoc.1999.1067","article-title":"Sigma-2 receptors as a biomarker of proliferation in solid tumours","volume":"82","author":"Wheeler","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2026.107519_bib0051","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872600093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:53:38Z","timestamp":1779710018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872600093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"alternative-id":["S092809872600093X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107519","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustainable chemistry and preclinical characterization of RC-106\u00b7HCl: A brain-penetrant pan sigma receptor modulator for glioblastoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107519"}}